A recent study indicates that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional lifestyle plans.
Findings released in a major medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing these drugs should be informed of the risk of quick rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment mass within about a year and a half.
Analyzing Therapies
The analysis, which examined dozens of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
The team note that people who lose weight through lifestyle changes alone generally see a more gradual weight regain—around 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts suggest the mode of action of the jabs is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to produce less of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals say that, given the high risk of weight regain, the treatment might need to be life-long.
This opinion is supported by drug manufacturers, who say that the results "emphasize the long-term nature of obesity," comparing it to managing diseases like hypertension.
User Accounts
People who have stopped the jabs describe a sudden resurgence of appetite.
"I experienced something activating and you're instantly starving," described a patient.
This challenge is compounded if patients have not established lasting lifestyle or habit modifications during therapy.
Growing Interest
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, researchers caution that while these medications are effective agents for shedding pounds, they are not a permanent cure and long-term success likely depends on combined behavioural support.
